Does Jazz (JAZZ) Have the Potential to Rally 47.29% as Wall Street Analysts Expect?Zacks Investment Research • 10/17/23
Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023PRNewsWire • 10/16/23
Ligand's Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaBusiness Wire • 09/22/23
Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaPRNewsWire • 09/21/23
Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023PRNewsWire • 09/11/23
10 growth stocks that are trading at bargain prices, including Delta and Cheniere EnergyMarket Watch • 08/30/23
Pharmaceutical cannabis sales surge, clinical trials seeing broader disease focusProactive Investors • 08/30/23
Wall Street Analysts See a 51.66% Upside in Jazz (JAZZ): Can the Stock Really Move This High?Zacks Investment Research • 08/10/23
Jazz (JAZZ) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 08/10/23
Jazz Pharmaceuticals (JAZZ) Q2 Earnings and Revenues Top EstimatesZacks Investment Research • 08/09/23
Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial GuidancePRNewsWire • 08/09/23